Synergy Pharma (SGYP) Posts Q2 Loss of $0.23/Share

Synergy Pharma (NASDAQ: SGYP) reported Q2 EPS of ($0.23), $0.03 worse than the analyst estimate of ($0.20).

As of June 30, 2016, we had approximately $141.2 million of cash and cash equivalents on hand as compared to approximately $111.8 million cash and cash equivalents and available for sale securities as of December 31, 2015.

"Our exciting transformation from a purely research and development company into a fully integrated commercial organization continues unabated as we successfully advance and execute against our key strategic priorities,” said Gary S. Jacob, Chairman and Chief Executive Officer of Synergy Pharmaceuticals Inc. “These priorities are guided by our overarching mission to optimize the value of plecanatide and maximize shareholder value.”

“The rest of 2016 promises to be an exciting time as we expect top-line results in our two phase 3 IBS-C trials with plecanatide. We are especially pleased with our ongoing dialogue with the FDA, including the results of our recent mid-cycle review meeting. Building the right commercial strategy and having the ability to successfully execute on the launch plan requires a strong team and we are fortunate to be attracting talented leaders with relevant experience from across our industry. I am very proud of the Synergy organization which is committed to a successful launch of plecanatide and bringing this important new treatment option to patients suffering from CIC and IBS-C,” added Dr. Jacob.

For earnings history and earnings-related data on Synergy Pharma (SGYP) click here.

You May Also Be Interested In

• IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
• Royal Caribbean (RCL) Tops Q1 EPS by 45c, Misses on Revenue; Offers FY24 EPS Guidance
• Carrier Global (CARR) Tops Q1 EPS by 12c ; Offers Guidance